S. I. Parkhomenko

S. I. Parkhomenko

Auto-generated profile, based on publicly available information

S. I. Parkhomenko

Almazov National Medical Research Center

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskay
T. D. Glebovskay
DKD. V. Karpova
D. V. Karpova
OMOlga Moiseeva
Olga Moiseeva
Aim. Comparison of conservative and invasive treatment strategies in patients with intermediate-high risk pulmonary embolism (PE) based on a multimodal assessment of efficacy and safety.Material and methods. This single-center, open-label, randomized, comparative trial will include 100 patients with a verified diagnosis of PE with intermediate-high risk of 30-day mortality. Patients will be randomized 1:1 to standard anticoagulant therapy or selective low-dose alteplase transcatheter thrombolysis. Patients will be followed for 12 months. The primary endpoint is a decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. There are secondary endpoints: patient hemodynamic instability; ISTH major bleeding; Qanadli index decrease at 48 hours; degree of residual thrombosis with reduced perfusion at 3-6 months; incidence of post-thromboembolic syndrome at 3-6 months; 30-day, 90-day, and 1-year mortality.Conclusion. The study will provide important clinical data on the short- and long-term efficacy and safety of different treatment approaches in patients with intermediate-to-high-risk acute pulmonary embolism.

13 March 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskaya
T. D. Glebovskaya
KMK. N. Malikov
K. N. Malikov
NMN. V. Marukyan
N. V. Marukyan
MSM. A. Simakova
M. A. Simakova
Selective transcatheter thrombolysis (STT) in patients with pulmonary embolism (PE) with an intermediatehigh risk of 30-day mortality is an option for rapid lung reperfusion with a decrease in right ventricular (RV) afterload, which largely determines the prognosis of patients.Objective. Comparison of the efficacy of STT using reduced doses of alteplase and routine conservative treatment of patients with PE with an intermediate-high risk of 30-day mortality using a retrospective analysis of the data from Almazov National Medical Research Centre.Design and methods. The retrospective single-center study included 45 patients (18 men (40 %) and 27 women (60 %)) admitted to the anaesthesiology and resuscitation department of the Almazov National Medical Research Centre from January 1, 2021 to May 1, 2022 with the confirmed diagnosis of acute PE. Intermediate-high risk patients (22 people (57,9 %)) were divided into two groups according to the treatment strategy: the group receiving standard anticoagulant therapy (n = 15 (68,2 %)) and the group with STT by alteplase at a total dose of 50 mg (n = 7 (31,8 %)). In order to assess the effectiveness of treatment, the main laboratory and instrumental indicators were compared based on data from the medical information system.Results. Baseline clinical characteristics of the compared groups did not differ. Systolic pressure in the pulmonary artery (SPPA) in the transcatheter treatment group decreased from 59 [50; 82] to 35 [30; 65] mmHg; in the conservative treatment group: from 65 [50; 70] to 52 [40; 59] mmHg. In the selective thrombolysis group, there was a significant trend for a greater decrease SPPA compared to the anticoagulant therapy group: –25 [–29; –3] versus — 10 [–23; –6] mmHg, р = 0,047. There was a significant change in the level of leukocytes and platelets in the group of transcatheter treatment versus anticoagulant therapy: –5,0 [6,1; 4,1] × 109/l vs –2,8 [4,3; 1,8] × 109/l (p = 0,017) and 130 [32; 181] × 1012/l vs 31 [2; 56] × 1012/l (р = 0,044). There were no significant differences in the change in the RV size between the groups. The groups did not differ in the total number of hemorrhagic complications. When bleeding was divided by severity (according to the TIMI classification), moderate bleeding was more common in the selective thrombolysis group (2 cases versus 0 with a conservative approach, p = 0,014). There were no differences in the duration of treatment in the anaesthesiology and resuscitation department and the terms of inpatient treatment.Conclusions. A single center retrospective study demonstrated the high quality of approaches to the diagnosis and treatment of PE in terms of current guidelines. The STT with reduced doses of alteplase was associated with a more significant decrease SPPA and normalization of hemogram parameters when compared to the standard treatment approach. At the same time, selective thrombolysis was associated with a higher risk of hemorrhagic complications. A prospective study of the efficacy and safety of prolonged STT with the selection of the dose of thrombolytic in patients with PE with an intermediate-high risk of 30-day mortality is needed.

4 June 2026 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskaya
T. D. Glebovskaya
VKV. S. Krasnov
V. S. Krasnov
OMOlga Moiseeva
Olga Moiseeva
Aim. To compare the efficacy and safety of ultrasound-assisted catheter-directed thrombolysis (UACDT) using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and a routine conservative approach with anticoagulant therapy (ACT) in patients with pulmonary embolism (PE) at intermediate-high risk for 30-day mortality. Material and methods. This single-center retrospective study included patients with confirmed intermediate-high-risk PE with thrombosis of the main or lobar branches of the pulmonary artery, no more than 14 days old. The patients were admitted to the cardiology intensive care units of the Almazov National Medical Research Center between January and December 2025. In accordance with the applied treatment strategy, patients were divided into 2 following groups: the UACDT group using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and the ACT group. After 48 hours, the effectiveness of the treatment was assessed as follows: the incidence of decompensated hemodynamics episodes, the changes of right ventricle to left ventricle basal diameter ratio (RV/LV), decrease in the Qanadli score and the increase in residual peripheral flow according to computed tomography pulmonary angiography (CTPA), as well as the changes of right ventricular function echocardiographic parameters. Safety criteria included the incidence of minor and major bleeding. A telephone survey of patients was conducted one month after discharge to assess long-term outcomes. Results. The study included 41 patients, which were divided into 2 groups: ACT group — 21 patients; UACDT group — 20 patients. The endovascular treatment group showed a more pronounced reduction in right heart overload: Δ RV/LV according to CTPA was 0,40 [0,20; 0,70] in the UACDT group vs 0,03 [0,00; 0,40] in the ACT group (p=0,012). A reduction in the RV/LV ratio of more than 20% from baseline was achieved in 74% of cases in the UACDT group vs 30% of cases in the ACT group (p=0,010). According to echocardiography, there was a decrease in the right ventricular diameter by 11,0 [6,7; 13,8] mm in the UACDT group vs 6,0 [1,5; 8,5] mm in the ACT group (p=0,015), a decrease in the right atrial area by 5,20 [0,67; 6,25] cm 2 in the UACDT group vs 0,0 [-1,0; 2,8] cm 2 in the ACT group (p=0,050), a reduction in the inferior vena cava diameter by 2,0 [1,0; 6,0] mm in the UACDT group vs 0,0 [-0,5; 2,0] in the ACT group (p=0,040). In 2 cases (10%) in the UACDT group and in 6 cases (29%) in the conservative ACT group, hemodynamic destabilization was recorded (p=0,238), which served as the basis for "rescue" systemic thrombolytic therapy. Hemorrhagic events occurred in 5 cases (25,0%) in the UACDT group and in 2 cases (9,5%) in the ACT group (p=0,538). The incidence of minor and major bleeding was comparable between the groups as follows: 4 minor bleeding events in the UACDT group vs 2 in the ACT group (p=0,992) and 1 major bleeding event in the UACDT group vs 0 in the ACT group (p>0,999). Fatal outcomes were recorded in 1 case (5%) in the UACDT group and in 3 cases (14%) in the ACT group (p=0,606). Conclusion . There is a higher efficacy of UACDT in the form of a reduction in right ventricular overload in patients with intermediate-high-risk PE when compared with standard ACT with a comparable safety profile.

10 October 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
SPS. I. Parkhomenko
S. I. Parkhomenko
MSM. A. Simakova
M. A. Simakova
OMOlga Moiseeva
Olga Moiseeva
Aim. To study the results of long-term follow-up of patients with pulmonary embolism (PE) of intermediate and high 30-day mortality risk.Material and methods. This retrospective study included 53 patients (45,3% men) with intermediateand high-risk PE, hospitalized at the Almazov National Medical Research Center from 2019 to 2020. The mean follow-up period was 20,9 [4,0; 33,5] months. The data were obtained from the health information system, as well as through phone calls.Results. Seven patients (13,2%) were classified as high, 29 (54,7%) as intermediate-high, and 17 (32,1%) as intermediate-low risk for 30-day mortality. Systemic thrombolytic therapy was performed in 11,3%, and selective transcatheter thrombolysis was performed in 24,5%. Of the 33 patients with available data, 23 (69,7%) attended in-person outpatient appointments. Another 10 (30,3%) patients were interviewed by telephone. Cancer screening was recommended to 36 (73,5%) patients, but the recommendation was followed only in a quarter of cases and papillary thyroid cancer was detected in one patient. Examination for thrombophilia was recommended for 20 (40,8%) patients, while 12 (60,0%) patients underwent it, 5 (41,6%) of whom were found to have hereditary thrombophilia. After discharge, 15 (30,6%) patients underwent control echocardiography, and 8 (16,3%) patients underwent repeat computed tomography pulmonary angiography. Chronic thromboembolic pulmonary disease was diagnosed in two cases, and chronic thromboembolic pulmonary hypertension was confirmed in one patient. Upon discharge, 30 (61,2%) patients were prescribed direct oral anticoagulants, 15 (30,5%) — vitamin K antagonists, 4 (8,2%) — low molecular weight heparin. The median duration of anticoagulant therapy was 22 [7,5; 31,5] months, with 20 (69,0%) patients receiving anticoagulants for >12 months. Outpatient bleeding was observed in 4 (13,8%) patients, all of which were recognized minor according to the International Society on Thrombosis and Haemostasis (ISTH) classification. No recurrence of deep vein thrombosis and/or PE was observed. After discharge, 3 (6,1%) deaths were recorded, the causes of which were unknown. One-year survival rate was 88%.Conclusion. There is insufficient patient compliance with discharge recommendations and low continuity of inpatient and outpatient treatment of patients with PE. Further implementation of the algorithm for outpatient management of patients after PE is required, which will allow making decisions on anticoagulant therapy and effectively and timely identifying PE consequences.

30 June 2023 in Patologiya krovoobrashcheniya i kardiokhirurgiya
Verified
Journal Article
Open access
PDF file
KPK.A. Pishchulov
K.A. Pishchulov
MSM.A. Simakova
M.A. Simakova
Vitaliy Leonidovich LukinovVitaliy Leonidovich Lukinov
Vitaliy Leonidovich Lukinov
SPS.I. Parkhomenko
S.I. Parkhomenko
NVN.E. Voinov
N.E. Voinov
OMOlga Moiseeva
Olga Moiseeva
Background: Ranking third in the cause of death structure, venous thromboembolism (VTE) is a frequent complication in patients with central nervous system tumors.Objective: To assess the incidence of venous thrombosis and its risk factors in glioma patients based on retrospective data.Methods: Our retrospective study included 186 glioma patients from the Neurosurgery Department of Almazov National Medical Research Centre.Results: The VTE incidence was 8% in patients with brain neoplasms. Comparative analysis of 2 groups to identify VTE predictors showed that the probability of thrombosis increases with factors leading to the patient immobilization: altered mental status (40% [n = 6] in the VTE group vs 18% [n = 30] in the non-VTE group, OR: 3.1 [95% СI: 0.8–10.6], P = .080), neurological deficit (67% [n = 50] vs 29% [n = 10], OR: 4.8 [95% СI: 1.4–18.7], P = .007), and bed rest for more than 3 days (33% vs 4%, OR: 13.1 [95% СI: 2.7–62.8], P < .001). Based on the validation results, Caprini and IMPROVEDD risk scores have high negative predictive values: 0.99 [95% СI: 0.93–1.00] vs 0.97 [95% СI: 0.93–0.99] (P = .317). Caprini risk score has a specificity of 48.2% and a sensitivity of 93.3% (AUC = 78.98); the threshold value for high-risk VTE detection is 5.5 points. IMPROVEDD risk score has a specificity of 82.5% and a sensitivity of 73.3% (AUC = 81.1); the threshold value for high-risk VTE detection is 4.5 points.Conclusion: Our study revealed VTE risk factors in glioma patients, such as neurological deficit, prolonged bed rest (more than 3 days), and a high-grade tumor. We demonstrated high negative predictive values of Caprini and IMPROVEDD risk scores and determined their threshold values to be validated in a further prospective study. Due to the high incidence of VTE and risks of hemorrhage in patients with central nervous system tumors, personalized venous thrombosis risk calculators should be developed, providing for features of thrombosis pathogenesis in this patient group. Received 12 December 2022. Revised 7 April 2023. Accepted 31 May 2023. Funding: The study was supported by Ministry of Science and Higher Education of Russian Federation (No. 075-15-2022-301). Conflict of interest: The authors declare no conflict of interest. Contribution of the authorsConception and study design: K.A. Pishchulov, M.A. SimakovaData collection and analysis: K.A. Pishchulov, S.I. ParkhomenkoStatistical analysis: V.L. LukinovDrafting the article: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. MoiseevaCritical revision of the article: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. MoiseevaFinal approval of the version to be published: K.A. Pishchulov, M.A. Simakova, V.L. Lukinov, S.I. Parkhomenko, N.E. Voinov, S.S. Sklyar, O.M. Moiseeva